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Abstract 
Subcellular membrane systems are highly enriched in dolichol, whose role in organelle 
homeostasis and endosomal-lysosomal pathway remains largely unclear besides being 
involved in protein glycosylation. DHDDS encodes for the catalytic subunit (DHDDS) of the 
enzyme cis-prenyltransferase (cis-PTase), involved in dolichol biosynthesis and dolichol-
dependent protein glycosylation in the endoplasmic reticulum. An autosomal recessive form of 
retinitis pigmentosa (retinitis pigmentosa 59) has been associated with a recurrent DHDDS 
variant. Moreover, two recurring de novo substitutions were detected in a few cases presenting 
with neurodevelopmental disorder, epilepsy, and movement disorder. 
We evaluated a large cohort of patients (n=25) with de novo pathogenic variants in 
DHDDS and provided the first systematic description of the clinical features and long-term 
outcome of this new neurodevelopmental and neurodegenerative disorder. The functional 
impact of the identified variants was explored by yeast complementation system and enzymatic 
assay. 
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Patients presented during infancy or childhood with a variable association of 
neurodevelopmental disorder, generalized epilepsy, action myoclonus/cortical tremor, and 
ataxia. Later in the disease course they experienced a slow neurological decline with the 
emergence of hyperkinetic and/or hypokinetic movement disorder, cognitive deterioration, and 
psychiatric disturbances. Storage of lipidic material and altered lysosomes were detected in 
myelinated fibers and fibroblasts, suggesting a dysfunction of the lysosomal enzymatic 
scavenger machinery. Serum glycoprotein hypoglycosylation was not detected and, in contrast 
to retinitis pigmentosa and other congenital disorders of glycosylation involving dolichol 
metabolism, the urinary dolichol D18/D19 ratio was normal. Mapping the disease-causing 
variants into the protein structure revealed that most of them clustered around the active site of 
the DHDDS subunit. Functional studies using yeast complementation assay and in vitro activity 
measurements confirmed that these changes affected the catalytic activity of the cis-PTase and 
showed growth defect in yeast complementation system as compared with the wild-type 
enzyme and retinitis pigmentosa-associated protein.  
 In conclusion, we characterized a distinctive neurodegenerative disorder due to de novo 
DHDDS variants, which clinically belongs to the spectrum of genetic progressive 
encephalopathies with myoclonus. Clinical and biochemical data from this cohort depicted a 
condition at the intersection of congenital disorders of glycosylation and inherited storage 
diseases with several features akin to of progressive myoclonus epilepsy such as neuronal 
ceroid lipofuscinosis and other lysosomal disorders.
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Introduction 
DHDDS (MIM*608172) encodes for the dehydrodolichyl diphosphate synthase subunit 
DHDDS, which in a complex with NgBR  (also termed Nogo-B Receptor) encoded by the 
NUS1 gene, constitutes the cis-prenyltransferase (cis-PTase), a branch point enzyme of the 
mevalonate pathway.  Cis-PTase is  located in the endoplasmic reticulum (ER) and is involved 
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in the biosynthesis of dolichyl monophosphate (Dol-P), an essential lipid serving as a glycosyl 
moiety carrier for protein N-glycosylation and as a carrier of dolichol-linked monosaccharide 
donors (Dol-P-Glc and Dol-P-Man) for O-mannosylation, C-mannosylation, and 
glycosylphosphatidylinositol (GPI) anchor formation.1,2 The structure of the eukaryotic 
enzyme as well as the mechanism through which DHDDS and NgBR stabilize each other, 
which is crucial for cis-PTase activity,3-5 has recently been clarified.2,6  Dolichols size varies 
between species and is determined by the given cis-PTase. In humans, DHDDS determines the 
number of isoprenoid units,6 that is commonly between 17 and 20, with a preponderance of 
dolichol-19 (D19).7
Protein N-glycosylation is a post translational modification crucial to protein folding, 
oligomerization, and intracellular sorting and transport. Molecular defects in genes involved in 
N-glycans biosynthesis belong to a family of metabolic disorders, collectively known as 
congenital disorders of glycosylation (CDGs).8,9 These diseases share an abnormal pattern of 
protein or lipid glycosylation and major nervous system involvement in the context of 
multisystemic disease. CDG subtypes with autosomal recessive defects in dolichol 
biosynthesis (DHDDS-CDG, SRD5A3-CDG, NUS1-CDG, and DOLK-CDG)10-12 have been 
reported, and most are detectable by routine CDG screening of serum transferrin via isoelectric 
focusing or mass spectrometry. 
Defects in the dolichol oligosaccharide assembly pathway cause accumulation of 
underglycosylated misfolded glycoproteins driving a chronic induction of the unfolded protein 
response pathway and ER stress, along with apoptosis and regeneration.13,14 A marked 
induction of ER stress and impaired N-linked glycosylation has also been observed in NUS1 
mutant fibroblasts, in association with intralysosomal cholesterol storage as seen in Niemann 
Pick type C disease.4
Despite the crucial role of dolichol synthesis in protein glycosylation in several tissues, 
germline mutations in DHDDS have only recently been associated with a complex multisystem 
phenotype in an individual exhibiting intrauterine growth deficiency, micropenis, 
hepatomegaly, renal failure, axial hypotonia, increased appendicular tone, severe global 
developmental delay (GDD) and refractory epilepsy, who died at eight months in status 
epilepticus. Analysis of skin fibroblasts revealed variable amounts of truncated dolichol and 
protein-linked N-glycans. This condition was associated with biallelic loss-of-function 
mutations and a CDG type I pattern of glycosylation.15 
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A recurrent homozygous variant in DHDDS (c.124A>G; p.Lys42Glu) was found in 
consanguineous families with non-syndromic retinitis pigmentosa (RP type 59).16-19 In these 
patients, D18 becomes the dominant species, with altered plasma and urinary D18/D19 ratios.20
Two additional recurrent pathogenic variants, i.e. p.Arg37His and p.Arg211Gln, have been 
reported in 7 individuals from unrelated  families with intellectual disability (ID), epilepsy, 
tremor, myoclonus, and movement disorder (MD).21-23 The p.Arg37His variant falls in an 
evolutionary conserved stretch of 5 amino acid residues (pos. 34-38), which corresponds to the 
catalytic domain of the enzyme.2,21 Crystal structure and mutagenesis studies demonstrated that 
Arg211 is critical in homoallylic binding to the isopentenyl diphosphate (IPP) substrate.2 
Although generalized epilepsy, tremor, and ID seem to be the main features associated with de 
novo DHDDS missense mutations, available clinical information is very limited and detailed 
genotype-phenotype correlation is lacking. A dominant-negative mechanism has been 
proposed to explain the allelic heterogeneity associated with DHDDS-related disorders.23 
Given the shared metabolic pathway, de novo variants in NUS1 have recently been associated 
with a clinical phenotype that overlaps with that described for de novo DHDDS pathogenic 
variants, namely ID, well controlled generalized epilepsy, prominent tremor/myoclonus, 
ataxia, and parkinsonism with a slowly progressive course.21,24,25 NUS1 variants were reported 
in isolated early-onset Parkinson’s disease.26 A homozygous NUS1 variant was described in a 
patient with severe neurological impairment, refractory epilepsy and congenital disorder of 
glycosylation.4
In this study we delineated the clinical phenotype associated with dominant DHDDS variants 
through the long term clinical observation of a large cohort of patients. We provided the first 
genotype-phenotype correlation analysis through functional characterization of reported 
DHDDS variants using yeast complementation and enzymatic assays. We also confirmed the 
role of the NgBR-DHDDS complex dysfunction in early onset neurodevelopmental and 
neurological disorders including myoclonus syndromes.
Materials and methods 
Patients
We collected clinical and molecular data of 25 patients from 24 unrelated families with likely 
pathogenic/pathogenic variants in DHDDS from different clinical centers in Europe, United 
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States, and Canada through international clinical collaborations and networking 
(GeneMatcher).27  Three patients (Pts 1-3) were previously reported with limited clinical data 
in Hamdan et al.21 
For each confirmed case, the referring physician completed a case review and returned pseudo-
anonymized data including developmental, neurological, behavioral, and epilepsy medical 
history, metabolic studies, electroencephalograms (EEGs), and neuroimaging data. Seizure 
types were classified using the International League Against Epilepsy (ILAE) criteria,28 or in 
more descriptive terms when the seizure phenomenology did not fit this classification 
terminology. Patients were evaluated according to developmental and cognitive functioning 
scales routinely used in the participating centers. Written informed consent was locally 
obtained for all participants. 
Molecular genetic investigations and in silico modelling
The DHDDS (NM_024887) pathogenic variants  reported herein were all identified by clinical 
(19/25) or research (5/25) whole exome sequencing (WES), except for one which was 
identified by research whole genome sequencing (WGS) (Supplementary Table 1). With the 
exception of a single-residue deletion (Lys42) documented in a single patient, they were mostly 
missense. In 22 of the 23 tested families, direct Sanger sequencing confirmed the de novo 
origin of the DHDDS variant. In family 4, segregation analysis documented mosaicism 
(p.Arg211Gln) in the father. Parental genomic DNA specimens were not available in family 
12 (p.Arg37His). In both cases, the identified variants were recurrent and demonstrated to 
occur as de novo events in multiple instances. The clinical relevance of the identified variants 
was assessed using the American College of Medical Genetics and Genomics (ACMG) 
guidelines for variant interpretation (Supplementary Table 1A).29,30
Mapping of the de novo DHDDS mutations was achieved using the previously solved crystal 
structure of human NgBR/DHDDS enzyme in complex with Mg2+ and IPP substrate (PDB ID: 
6W2L). PyMOL software was used to model the location and binding interactions of individual 
mutations. 
Functional characterization of DHDDS missense variants
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Detailed methods for expression and purification of the NgBR/DHDDS complex, cis-PTase 
activity assay, and yeast complementation assay are available in the supplementary methods 
and materials.
Metabolic studies 
Detailed methods for glycosylation profiling through liquid chromatography combined with 
tandem mass spectrometry (LC-MS/MS) analysis of serum transferrin (TF) and dolichol 
content analysis in urine by LC-MS/MS are available in the supplementary methods and 
materials.31-33
Data availability 
The authors confirm that the data supporting the findings of this study are available within the 
article and its supplementary data.
Results 
Clinical description
We studied 25 patients (17 males and 8 females) aged 4 to 59 years. Eleven were young adults 
or adults (age range 18-59 years). Most patients were born from normal pregnancies and 
deliveries, with normal growth parameters and neonatal examinations. Detailed descriptions of 
neurodevelopmental, epileptic, and motor features are reported in Table 1 and Supplementary 
Table 1. Extensive clinical reports for 14/25 patients are available in the supplementary 
materials.
Presenting features and disease evolution
Initial signs of neurodevelopmental and/or neurological impairment were noticed during 
infancy in 22/25 patients (age at symptom onset: range 1-24 months, median 12 months). 
Patients 17 and 23, now 44 and 16 years old, who manifested their initial clinical symptoms at 
age 5 and 3, respectively, had the latest disease onset and mildest phenotype. 
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GDD with or without hypotonia was the most frequent presenting symptom (23/25 pts). 
Additional features frequently reported at onset included tremor and seizures. Ataxia was an 
early symptom in 6/25 patients. In two patients, parents reported a neurological regression 
beginning from early disease stages.
The combination of GDD and tremor occurred in 11/25 patients, four of whom also 
experienced seizures, thus manifesting the core triad of the condition from onset. 
Neurological deterioration was described in most patients (17/25), with no obvious genetic, 
demographic, or clinical factor influencing prognosis. Seven patients (Pts 1,6,9,10,13,19, and 
21) exhibited prominent cognitive decline. Progression occurs over years or decades.  In some 
patients, there were periods of rapid deterioration while in others progression was gradual. 
Stepwise neurological deterioration with multiple phases of regression was observed in patients 
1,9, and 12. The outcomes of patients 1 and 19, respectively 39 and 17 years, were particularly 
severe with intense fatigue, autonomic dysregulation (bladder, temperature, heart rate, 
breathing), and dementia with akinetic mutism. 
Neurodevelopmental, cognitive and behavioral phenotype
All patients except one had ID, which was severe in 12, moderate in 6 and mild in 5. Patient 8 
had normal development up to 18 months of age, after which developmental issues were first 
noticed in relation to epilepsy onset. Patients were able to sit between 9-18 months, walk 
between 13-36 months, pronounce their first words after 3 years and, in those with milder 
cognitive impairment, speak in sentences after 4-5 years of age. 
Patient 17 graduated from high school and attended community college, achieving above-
average grades. Gross motor functioning was normal and he was an excellent swimmer and 
skier. He exhibited absence seizures since age of 5 years, myoclonus at 16 years and rare GTCS 
in adulthood. Patient 12 complained of tremor from the age of 10 years and had his first 
epileptic seizures at the age of 19 years. He showed borderline intellectual functioning, tough 
it was compatible with a normal employment in adulthood. 
Relevant behavioral and/or neuropsychiatric comorbidities were reported in the majority of 
patients (18/25) (Fig.1, Table 1, Supplementary results). Four patients presented a severe 
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psychiatric outcome with psychosis and/or catatonia in advanced disease stage (adolescence to 
adulthood) (Pts 1,6,13,and 17). 
Epilepsy
Epilepsy, reported in 22/25 patients, was a core feature of the disorder. Age at seizure onset 
ranged from 6 months to 10 years. Thirteen/25 patients had infantile onset epilepsy (birth-2 
years), 8/25 had childhood onset epilepsy (3-12 years), and one patient (Pt 12) had GTCS onset 
at 19 years. Febrile seizures (myoclonic, absence, or GTCS) were reported in 7/25 and were 
part of the presenting features (11-25 months of age) in 6/25 patients (Pts 3,7,8,10,17,24,and 
25), preceding afebrile seizure onset. In patient 7 seizures started after vaccination. 
Photosensitivity was observed in 5 patients (Pts 1,18,19,24,and 25).
Generalized epilepsy including myoclonic-atonic epilepsy was reported in 21/25 patients with 
absence (15/25), GTC (13/25), myoclonic (8/25), and atonic (6/25) being the most frequent 
seizure types. Distribution of seizure types is summarized in Table 1 and Fig.1. Absence 
seizures included typical absences, atypical absences, myoclonic absences, and absences with 
eyelid myoclonia (Supplemental table 1). Patients 9, 18 and 20 had frequent nocturnal seizures, 
which were tonic in patients 9 and 20, whereas patient 18 had GTCS.  Twenty out of 25 patients 
presented multiple seizure types, typically 2-4. 
Epilepsy was well controlled with anti-epileptic drugs (AEDs) in 13/25 patients, while 9 
patients had drug resistant seizures. All patients with childhood onset epilepsy (Pts 1,6,9,10, 
and 13-17) were well controlled under AED therapy. Among patients with infantile onset 
epilepsy, 9/13 had drug-resistant epilepsy non-responsive to combinations of several 
conventional AEDs, and 4/13 were well-controlled using valproate alone or in combination 
with levetiracetam, or clobazam.
Generalized EEG abnormalities were reported in 16/22 epileptic patients. EEG recordings in 
12/22 patients showed bursts of ictal and interictal generalized slow spike and wave complexes 
(2-4 Hz), sometimes predominantly on the frontal region, in association with generalized slow 
activity, and/or diffuse slowing of the posterior dominant rhythm, or abnormal background 
activity. Ictal slow spike-wave complexes correlated with absences, eyelid myoclonia, 
myoclonic seizures, and atonic events (head drops, falls) (Pts 1,3,4,7,8,10,18,19,21,22, and 25) 
(Fig.2).
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Epilepsy usually improved or resolved from adolescence and epileptiform abnormalities 
disappeared over the disease course (Supplementary results). The most effective AEDs, alone 
or in combination were valproate (11/22), levetiracetam (8/22), clonazepam (6/22), and 
clobazam (6/22); other drugs were less effective, including lamotrigine (2/22), zonisamide 
(3/22), topiramate (2/22), ethosuximide (1/22), phenobarbital (1/22), primidone (1/22), 
lacosamide (1/22) and brivaracetam (1/22). Levetiracetam led to seizures  worsening in patient 
8.
Movement disorder
Movement disorder, generally as bilateral distal intention and postural tremor/myoclonus of 
the upper limbs (Pts 1-5,8,15,18,19,and 23), was part of the clinical presentation in most of 
patients (14/25), detected in the first months of life in some patients (Pts 3,5,8,15, and 18), and 
sometimes associated with ataxia (Pts 1-5,18,19,and 21) and/or hypotonia (6/25). Patients 1, 2 
and 23 underwent neurophysiological studies with back averaged EEG which demonstrated a 
cortical origin of tremor. 
Tremor tended to change over time in terms of distribution and type with involvement of the 
trunk and lower extremities and onset of rest tremor superimposed to the already present action 
and postural components (Pts 1,6,8,12,15,19, and 21) (videos 1-5, available from figshare 
https://doi.org/10.6084/m9.figshare.15106032.v1). Tremor became continuous over time, 
exacerbated by sudden lights, loud noises, stress, and movement (pts 1, 8, 12, and 16; videos 
1,2, and 5). Facial involvement, particularly of the eyebrows and mouth, was observed in 8/25 
patients (Pts 1, 6-8, and 11-14) (videos 1-5). Periodic exacerbations of tremor/myoclonus 
lasting hours to days (Pts 1 and 2) (video 1) and episodic weakness requiring hospitalization 
(Pts 1 and 9) were reported. 
At follow up 24/25 patients had a MD. In most of them (14/25), a complex pattern of MD 
emerged over time (Pts 1,6-9,11,12,15,18-21,24,and 25) including ataxic features (Pts 2-
5,8,12-16,18- 23, and 25), dystonic posturing of the upper and/or lower limbs (Pts 1, 6,8,11,15, 
and 18-20) (video 2), parkinsonism (Pts 1, 6,11, 12,18-20, and 24), and chorea (Pts 7, 9,16, and 
22) (Fig.1 and Table 1). Fluctuations in tremor and other MDs severity were observed in 
patients 1,8,11,18,19, and 22. Parkinsonism with rigidity, rest tremor, bradykinesia and 
hypomimia was a late disease feature, which developed gradually from adolescence (video 1 
and 2). Over the disease course 8/25 patients developed speech abnormalities such as 
hypophonic and slow speech (Pts 1,20, and 23), dysarthria (Pts 3,8,11,12, and 19), and loss of 
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speech/anarthria (Pts 1 and 6). Pyramidal signs were reported in 5/24 patients (Pts 5,6,12,19, 
and 21).
Most patients did not receive treatment for MD (21/25) and epilepsy treatment had a relatively 
mild effect on tremor and MDs. Piracetam was ineffective for cortical tremor in patient 1, while 
a partial response was observed with high doses of clonazepam (up to 9 mg/day). Parkinsonism 
didn’t respond to levodopa which instead increased impulsivity and hyperactivity. 
Interestingly, very low doses of risperidone (0,5 mg/day) or tetrabenazine (6.25 mg/day) were 
able to control the severity of myoclonic episodes in advanced disease stage, while higher 
dosages induced akinetic status. In patient 17 tremor responded to propranolol while in patient 
24 a mild effect of benzodiazepines on cortical tremor was observed. 
Associated features
Dysmorphisms were reported in a subgroup of patients (Fig. 3). The most recurrent features 
were altered dental architecture with wide spaced or missing teeth (Pts 2,4, and 7) and 
generalized hypertrichosis with dark hair and thick eyebrows (Pts 1,6,9, and 15). Patient 15 
developed axillary and pubic hair at age 4. Other dysmorphic features were wide-set almond-
shaped eyes (Pts 7 and 9), upslanted palpebral fissures (Pts 4 and 7), flat/concave nasal bridge 
(Pts 4 and 7), prominent supraorbital ridge (Pts 7,9, and 12), high frontal airline (Pt 7), large 
mouth with full lips (Pt 7), high palate (Pt 2), bifid uvula (Pt 9), thick ear lobes (Pt 7), fetal 
pads (Pt 7), and first toe clinodactyly (Pt 4). Sagittal craniosynostosis was surgically repaired 
at 3 months of age in patient 15. Hyperpigmentation at the right side of the thorax was seen in 
patient 2. 
Gastrointestinal issues with periods of severe constipation were reported in patients 1 and 4, 
while recurrent abdominal pain and vomiting were reported in patient 20. At the age of 14, 
patient 9 was diagnosed with Crohn disease and successfully treated with infliximab. Patient 
17 underwent resection of a dysplastic rectal polyp at the age of 42 years with negative genetic 
testing for hereditary cancer predisposition. Patient 1 had fatty liver disease with 
hypercholesterolemia, increased levels of Gamma-glutamyl transferase and milder increase of 
serum transaminase. 
Conjunctival telangiectasias was observed in patients 1 and 20. Patient 20 was affected by a 
complex autoinflammatory disorder characterized by recurrent arthralgia of the knees, 
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episcleritis, intermittent fever, and suffered from an acute episode of purpura with 
erythrocyturia/hematuria, and increased CRP, and IgA, which significantly improved after 
steroid treatment. Skin biopsy was diagnostic for small vessel vasculitis demonstrating 
perivascular leucocyte infiltrates. 
Brain imaging 
Brain MRIs, available for 24/25 patients, were normal in 23/24, with 6 patients (Pts 1,2,9, 
15,17, and 21) scanned more than once at different disease stages. Patient 1 had normal brain 
imaging up to the age of 27. At the age of 37, he started to severely deteriorate. Brain MRI 
showed T2/FLAIR subcortical hyperintense non-enhancing foci localized to the frontal, 
temporo-occipital and visual cortices bilaterally with prominent involvement of calcarine 
cortex (Fig. 4A). A follow-up study at 10 months demonstrated severe and diffuse cortical and 
subcortical atrophy (Fig. 4B) including previously hyperintense areas, the dorsal striatum with 
prominent caudate involvement, and cerebellum. 1H-MRS demonstrated decreased N-
acetylaspartate (NAA) peak and NAA/choline (Cho) ratio at the level of the caudate lesions, 
thus confirming neuronal degeneration. 1H-MRS was performed and resulted normal in 4/24 
patients. Stable corpus callosum thickening was documented in patient 21. MRI of the spinal 
cord of patient 17 showed a T5-T11 syrinx, which was stable on serial imaging from ages 35-
43 years. 
Metabolic features
CDG screening was performed by isoelectric focusing of plasma transferrin (TF) and resulted 
normal in 12/25 patients. Mass spectrometry analysis of plasma TF was subsequently 
performed in 5/25 patients, two of which showing marginally abnormal glycosylation (Table 
1). Urinary dolichol isoforms (D18/D19 ratio) were evaluated and resulted normal as compared 
with age-matched controls in 4/25 patients. Hypercholesterolemia without 
hypertriglyceridemia was reported in 3/25 patients.
Ultrastructural analysis of the skin biopsy from patient 1 showed osmiophilic material deposits 
in myelinated fibers. Numerous single membrane-surrounded vacuoles containing lamellated 
membrane structures resembling phospholipids or other lipid-like material were observed in 
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the axons of myelinated fibers (Fig. 5A-D). Cholesterol-like deposits associated with glycogen 
were evident in the cytoplasm of Schwann cells. In a small percentage of stroma fibroblasts 
large secondary lysosomes filled with different electron-density substances were found in the 
cytoplasm (Fig. 5E-F). Axillary skin biopsy revealed PAS positive bodies in eccrine glands in 
patients 6. 
Genetic findings and genotype-phenotype correlation 
Fifteen individuals carried two previously reported DHDDS pathogenic variants (p.Arg37His 
and p.Arg211Gln),21 while 10 harbored new pathogenic/likely pathogenic variants 
(p.Gly35Glu, p.Arg37Cys, p.Lys42del, p.Arg205Gln, p.Ser213Asn, and p.Pro233Arg) 
(Supplementary Tables 1, 1A). Twenty-three variants were validated as  de novo events, while 
parental mosaicism was demonstrated in family 4, in which the asymptomatic father was found 
to be mosaic.
The most recurrent variant was p.Arg211Gln, which was detected in 11/25 patients (patients 1 
and 2 were previously reported with limited clinical information by Hamdan et al.).21 Four out 
of 25 patients had the previously reported p.Arg37His change21,22 (patient 3 was previously 
reported previously with limited clinical information by Hamdan et al.).21 Newly identified 
variants were distributed as follows: four subjects carried the p.Arg37Cys substitution, two 
patients carried the p.Gly35Glu, while p.Pro233Arg, p.Ser213Asn, p.Arg205Gln, and 
Lys42del were identified in single individuals.
None of these variants was predictive of disease severity in terms of cognitive functioning, 
epilepsy, and MD phenotype. Moreover, the phenotype associated with the three most frequent 
variants detected in this cohort, namely p.Arg37His, p.Arg37Cys, and p.Arg211Gln, did not 
differ significantly in terms of age of disease onset, clinical presentation pattern, or disease 
course. No specific variants were associated with a better cognitive outcome (Pts 
3,12,17,19,20,23), while disease course in patients less cognitively compromised (Pts 12,17, 
23) seemed to be characterized by a later onset and milder epilepsy and MD, regardless of the 
specific variant. Indeed, the p.Arg37His and p.Arg211Gln were found to occur with a 
substantially variable clinical phenotype. 
Some genotype-phenotype correlations, however, emerged in our cohort. Patients harboring 
the p.Arg37His change all suffered from febrile seizures as a presenting feature or during the 
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disease course and epilepsy remained well controlled in 3/4 patients. The p.Arg211Gln variant 
was also associated with a severe phenotype, with stepwise deterioration in 2/11 patients and 
fluctuations or exacerbations of MD in 3/11 patients. MD in this subgroup tended to become 
particularly severe over the disease course. Four out of 8 patients of this cohort who developed 
parkinsonism harbored the p.Arg211Gln variant. Among the 5 patients with severe psychiatric 
manifestations, 3 carried the p.Arg211Gln variant (Pts 1,6, and 17) while 2 carried the 
p.Arg37Cys variant (Pts 8 and 13).
Structural data
The recently resolved structure of the human NgBR/DHDDS complex2,6 was used to explore 
the structural and functional consequences of the identified disease-causing variants. The 
mutated residues are localized within the previously established cis-PTase catalytic domain of 
DHDDS (residues 25-265). As shown in Fig.6A, most amino acid changes affect residues that 
cluster around the active site of DHDDS and are involved in allylic (farnesyl diphosphate, FPP) 
and homoallylic (IPP) substrate binding. The β-phosphate group of the FPP substrate is 
hydrogen-bonded to the backbone amide of Gly35, which is localized on the P-loop, and is well 
established to be involved in FPP binding. Therefore, replacing Gly35 with Glu35 would result 
in steric clashes with nearby residues and hence perturb packing of the P-loop and potentially 
disrupt Arg38 conformation on the proceeding α1 helix, which is also involved in FPP binding. 
In addition, the side chain of Arg37 is stabilized by a network of salt bridges with the β-
phosphate group of FPP, Glu89 on DHDDS and the main chain carboxylate group of Lys293 on 
the C-terminus of NgBR (Fig.6B). Introducing a histidine residue at this position would abolish 
binding interactions with the β-phosphate group of FPP substrate as well as with the C-terminus 
of NgBR. The introduction of a cysteine at this position could be more detrimental due to the 
loss of a positive charge. Similarly, the side chains of Arg205 and Arg211 form salt bridges with 
the pyrophosphate of IPP (Fig. 6C), and replacement of either residue with Gln would eliminate 
binding interactions with IPP. Although substituting Ser213 with Asn can still maintain 
hydrogen bonding with the β-phosphate group of IPP, introducing a bulky side chain at this 
region would result in steric clashes with nearby residues, hence leading to structural 
destabilization. While the aforementioned residues are directly involved in substrate binding, 
Pro233 is an exception to this pattern. Pro233 is localized within a loop that connects βF with α7 
and seems to be involved in hydrophobic packing against Tyr39 on α1, harboring FPP binding 
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residues (Fig. 6D). Accordingly, substituting Pro with a charged residue like Arg could disrupt 
packing of the α1 helix and binding to the FPP substrate. Finally, previous structural and 
functional studies on the p.K42E substitution have already established its indirect role in FPP 
binding by stabilizing the α1-helix through a salt bridge formed with a conserved E234.2 
Similarly, a deletion at this position (ΔK42) could affect the stability of the structure as well as 
FPP substrate binding. 
Functional validation of de novo DHDDS missense variants: yeast 
complementation assay and enzymatic activity measurement
Yeast complementation assays were performed to functionally validate the identified variants.4 
As seen in Fig 7A, mutants containing DHDDSK42 were able to support the growth 
of rer2Δ/srt1Δ/nus1Δ yeast cells (lacking endogenous genes critical for cis-PTase activity) in 
a manner similar to that of wild type (WT) cis-PT and DHDDSK42E (a mutation underlying 
RP).5 DHDDSS213N causes slight growth defect suggesting that enzyme activity is below 20% 
and that DHDDSR211Q severely impairs yeast growth.  Finally, DHDDSG35E, DHDDSR37C, 
DHDDSR37H, DHDDSR205Q and DHDDSP233R did not support yeast growth, further confirming 
their predicted essential role in enzymatic activity. To expand the detection limit of our yeast 
complementation assay, we modified our system by expressing DHDDS from a single-copy 
plasmid under the native yeast RER2 promoter. Since NgBR is stable in yeast cells only when 
co-expressed with DHDDS and its co-expression from the single plasmid does not support the 
growth (data not shown), we generated yeast strains of interest co-expressing DHDDS from 
single-copy plasmid and NgBR from multi-copy plasmid.
Page 18 of 85









niversity of Torino user on 02 O
ctober 2021
We compared the growth rates of yeast expressing either WT or one of the DHDDS mutants 
using the yeast spot test (Fig. 7B) and kinetic growth assay (Supplemental Fig. 1) on yeast 
extract peptone dextrose (YPD) medium or YPD supplemented with lovastatin, an inhibitor of 
HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway responsible for 
substrate synthesis. The results showed that yeast cells harboring the mutated version of 
DHDDS displayed different degrees of growth delay in YPD medium, with a more pronounced 
phenotype at 37 °C. As expected, these cells were also more sensitive to lovastatin due to the 
low substrate levels. 
Next, we compared the steady-state activities of purified mutants to those of the WT complex. 
As shown in Fig. 4C, all mutants analyzed displayed lower enzymatic activity compared to the 
WT enzyme. In addition, mutations that did not support yeast growth (DHDDSG35E, 
DHDDSR37C, DHDDSR37H, DHDDSR205Q and DHDDSP233R) were able to incorporate 
radioactive IPP substrate within the detection limit range, suggesting that they formed a 
catalytically dead enzyme. Overall, enzymatic activity changes were proportional to the level 
of growth defect observed in our yeast studies. In summary, the data presented herein further 
support the pathogenicity of the identified de novo DHDDS variants.
Discussion 
DHDDS phenotypic spectrum
Here, we report a first comprehensive description of the phenotype associated with de novo 
DHDDS variants. We demonstrated that heterozygous DHDDS mutations are associated with 
a complex slowly progressive central nervous system disorder with broad functional 
consequences including cognitive impairment, abnormal motor control (myoclonus, cortical 
tremor, ataxia, MD), and epilepsy. 
We depicted a distinctive disorder presenting during infancy or childhood with 
neurodevelopmental and neurological findings including GDD/ID, epilepsy, myoclonic 
movements, and postural and intention tremor (with or without ataxia). Starting from the 
second decade of life, the disease followed a slow or stepwise pattern of progression, at times, 
punctuated by episodes of acute deterioration. Cortical tremor generalized, and further signs of 
diffuse neurological impairment appeared, including epilepsy (when not already present), 
hyperkinetic and hypokinetic MD, cognitive decline, and psychiatric disturbances. 
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The epileptic phenotype was characterized by febrile seizures at presentation, coexistence of 
multiple generalized seizure types, and an EEG pattern of ictal and interictal generalized slow 
spike-wave complexes, as also described in two previously reported patients with dominant 
mutations in DHDDS 22,23 and in a patient with heterozygous NUS1 pathogenic variants.25 
Neuroimaging studies do not contribute to diagnosis or clinical monitoring. No metabolic 
biomarkers have been associated with the disease. The electrophysiological investigations of 
the abnormal movements are in support of an exaggerated cortical hyperexcitability state as 
reported in other myoclonic syndromes. 23,40,41  
Consistent with this hypothesis, short latency somatosensory evoked potentials (SEPs) showed 
exaggerated cortical responses (giant SEPs) in a previously reported 15 year old girl with the 
most recurrent p.Arg211Gln variant and cortical myoclonic tremor,23 and back averaged EEG 
indicated a cortical origin of tremor in 3 patients of this cohort thus suggesting cortical tremor.
Functional impact of DHDDS pathogenic variants
We provided a first genotype-phenotype correlation analysis supported by functional studies 
using yeast complementation assay and in vitro activity measurements.
Mapping the disease-causing de novo DHDDS variants into the protein structure revealed that 
most cluster around the active site of the DHDDS subunit and likely directly affect enzymatic 
activity and/or substrate binding. Our findings indicated that all the identified variants formed 
cis-PTase with impaired/reduced enzymatic activity and show growth defects in yeast 
complementation assays. DHDDSK42 and DHDDSS213N had a less severe phenotype compared 
to the other mutants. The impact of these changes on yeast growth became evident only in spot 
test (37°C) and kinetic growth assay performed in the presence of lovastatin, but was 
significantly higher compared to that of the recessive RP-causing DHDDSK42E mutant.
Molecular mechanisms of DHDDS-related diseases
DHDDS encodes a protein involved in dolichol biosynthesis on the cytoplasmic face of the ER, 
where N-glycosylation, O-mannosylation, C-mannosylation and GPI-anchor synthesis occurs. 
Besides the presence of glycosylated dolichol species in the ER, dolichol is present in all 
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subcellular membrane systems. Free alcohol and phosphorylated and esterified dolichol, are 
detected in peroxisomes and are highly enriched in lysosomes, the plasma membrane and Golgi 
vesicles.34
Mitochondrial membranes and nuclei also contain a limited amount of dolichol. Furthermore, 
dolichol plays a more general role in membrane trafficking, particularly between the ER and 
the lysosomal-endosomal system.35 Given the ubiquity of dolichol in different cellular 
compartments, dolichol biosynthesis defects and accumulated dolichol precursors can 
presumably affect many other cellular processes independent of protein post-translational 
modifications. Interestingly, dolichol accumulation has been reported in neuronal ceroid 
lipofuscinosis (NCLs),36-38 in which retinal degeneration occurs, while alterations in 
dolichol/Dol-P levels have been reported in patients with Alzheimer disease.39
Understanding the molecular mechanisms of DHDDS-related diseases is not trivial. 
Before the recent description of autosomal dominant forms21-23, recessive inheritance was 
described in a fatal case with severe multi-organ involvement15 as well as in isolated RP.16-18 
Assuming that human cis-PTase forms a heterodimer under physiological conditions, variants 
with a loss-of-function/hypomorphic behavior may lead to dolichol levels that are below the 
threshold necessary to fulfil its various biological roles in cells. The dolichol threshold concept 
could explain why heterozygous parents and siblings of patients carrying the p.Lys42Glu 
substitution underlying RP or the p.Trp64*/p.Cys148Glufs changes (DHDDS) and 
p.Arg290His (NgBR)4 associated with CDG type I appear to be healthy individuals.15-18 Indeed, 
the probability of being loss-of-function intolerant (pLI score, gnomAD ver 2.1.1), a metric 
used to determine the tolerance of a gene for LOF variants, supports DHDDS is not 
haploinsufficient (pLI= 0.25).
Interestingly, a recent study on the human NgBR/DHDDS complex suggested a higher 
oligomerization state of the complex whereby the two heterodimers were depicted to form a 
tetramer.6 This observation introduces the possibility of a dominant-negative mechanism that 
may reduce cis-PTase activity of certain mutants to lower levels than expected. Based on these 
findings, we suggest the homozygosity for loss-of-function or strong hypomorphic variants 
underlies CDG type I (both DHDDS and NgBR), while de novo pathogenic variants are likely 
to have a dominant negative effect on heterodimer/tetramer assembly and function.
On the other hand, it has been suggested that p.Lys42Glu may affect only retinal 
photoreceptors because the highest level of DHDDS/NgBR enzymatic activity is required in 
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this tissue for opsin N-glycosylation.16 Consistent with zebrafish studies indicating that a slight 
downmodulation of the endogenous gene is sufficient to cause photoreceptor degeneration, 
whereas a stronger knockdown causes a more complex phenotype, this change might be 
tolerated outside the retina.17 This model, however, does not explain why the retina is not 
affected in subjects carrying dominant DHDDS pathogenic variants, suggesting a more 
complex scenario for these substitutions. In line of principle, single nucleotide changes at 
codon 42, not encompassing a CpG site, are predicted to lead to multiple amino acid 
substitutions, i.e. Gln and Glu (first position), Thr, Arg and Met (second position), and Asn 
(third position). The invariant association of RP with p.Lys42Glu suggests a neomorphic effect 
for this change or, more likely, a deleterious effect restricted to the retina (e.g., altered 
interaction of defective DHDDS with a photoreceptor-specific protein or a tissue-specific toxic 
effect of accumulating isoprenoid compounds)16,19. In line with this hypothesis, in patients with 
DHDDS-related RP as well as in other CDGs involving dolichol metabolism,32 D18 becomes 
the dominant species, with altered plasma and urinary D18/D19 ratios and a possible 
accumulation of damaging precursors in the retina.20 Of note, the urinary dolichol D18/D19 
ratio determined by LC-MS/MS was normal in patients carrying de novo DHDDS variants.
Finally, it is also worth noting that the broad phenotypic spectrum amongst patients 
harboring the common p.Arg211Gln mutation suggests additional factors, including 
environmental and genetic background, that may contribute to the final clinical picture.
Aberrant NgBR/DHDDS complex functioning is associated with 
a neurodegenerative disorder in the cortical myoclonus spectrum
The association between generalized epilepsy and cortical tremor or other myoclonic 
phenomena, which patients with AD pathogenic DHDDS and NUS1 variants share, places the 
two disorders in the differential diagnosis of several syndromes in the cortical myoclonus 
spectrum, including progressive myoclonus epilepsy-ataxia (PME/PMA), and, for patients with 
milder presentations, benign adult familial myoclonus epilepsy (BAFME).22,25,41
Furthermore, the relatively high MD incidence, including parkinsonism in patients with de 
novo DHDDS and NUS1 pathogenic variants, is indicative of a possible contribution of the 
NgBR-DHDDS complex to the pathogenesis of Parkinson’s disease and neurodegenerative 
processes. In line with this finding Guo et al. reported that NUS1 loss could reduce the number 
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of dopaminergic neurons with apoptosis in the fly brain.26
Overall, the prominent neurological phenotype of our cohort highlights the importance of 
dolichol metabolism in neuronal subcellular membrane systems and further broaden the clinical 
and biochemical characterization of DHDDS-related conditions, placing them in a spectrum 
that only partially overlaps with CDG type I. In line with this, serum glycoprotein 
hypoglycosylation was not observed in these patients and, in contrast to the RP phenotype20 
and other CDGs involving dolichol metabolism,4,32 the urinary dolichol D18/D19 ratio 
determined by LC-MS/MS was normal.
Instead, electron microscopy of skin biopsy revealed abundant lipid-like material storage in 
myelinated fibers and Schwann cells, and secondary lysosomes in stromal fibroblasts 
suggesting a dysfunction of lysosomal enzymatic digestion machinery. 
Consistently with this finding lysosomal cholesterol accumulation has been recently reported 
in fibroblasts of patients with de novo NUS1 and DHDDS pathogenic variants.42,43 Given that 
many lysosomal enzymes are highly N-glycosylated, hypo-glycosylation caused by impaired 
dolichol synthesis may be contributing factor to the neurological symptoms observed in the 
patients with defective DHDDS or NUS143.
The aberrant functioning of the ER-endolysosomal pathway and the association between 
cortical myoclonus, severe MD including parkinsonism, neurological deterioration, cerebral 
atrophy, and storage material in myelinated fibers and fibroblasts, supports the proximity of 
DHDDS related disorders to other inherited storage diseases such as NCLs and other lysosomal 
disorders. 
Additional functional studies with future generation of knockout/knockin mice and iPSC 
derived neuronal cell models could provide a full understanding of the consequences of these 
and other DHDDS mutations on cellular organelle dynamics, dolichol metabolism, mammalian 
brain development and neurodegeneration pathways. Many aspects of dolichol dependent 
glycosylation including N-glycosylation, several steps of synthesis, recycling and regulation of 
dolichol availability are still largely unknown.  This information would be critical not only to 
understand the biochemical underpinning of this disease, but also to consider the potential for 
specific disease-targeted therapeutic interventions.
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